Veracyte, Inc. - Common Stock (NQ:VCYT)

45.81 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting

September 21, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests

September 07, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies

September 06, 2023

From Veracyte, Inc.

Via Business Wire

Here's Why This Little-Known Growth Stock Is a Buy ↗

May 22, 2023

Analysts think this genomic test maker could have major upside in the next year.

Via The Motley Fool

Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? ↗

September 02, 2023

The genetic test maker is rapidly increasing test volumes.

Via The Motley Fool

Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

August 29, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

August 22, 2023

From Veracyte, Inc.

Via Business Wire

Looking Into Veracyte's Return On Capital Employed ↗

May 17, 2023

Via Benzinga

Recap: Veracyte Q1 Earnings ↗

May 04, 2023

Via Benzinga

Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego

August 15, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Second Quarter 2023 Financial Results

August 08, 2023

From Veracyte, Inc.

Via Business Wire

Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment

August 01, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023

July 19, 2023

From Veracyte, Inc.

Via Business Wire

Looking for Biotech AI Stocks? 3 Names That Will Benefit From the AI Boom ↗

July 08, 2023

AI is changing the face of biotechnology and drug discovery. Don't miss out on the next big boom in biotech, here are 3 stocks to consider.

Via InvestorPlace

New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer

June 20, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023

June 12, 2023

From Veracyte, Inc.

Via Business Wire

Market Mixes It Up With A Broad Rally ↗

June 05, 2023

Biotech stocks remain sluggish but the longer-term outlook for breakthrough therapies - gene therapy, obesity, CNS, RNA - remain positive.

Via Talk Markets

Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June

May 31, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

Via FinancialNewsMedia

New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer

May 25, 2023

From Veracyte, Inc.

Via Business Wire

New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer

May 24, 2023

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in Upcoming Investor Conferences

May 23, 2023

From Veracyte, Inc.

Via Business Wire

Time To Play Small Cap Life Science Stocks ↗

May 15, 2023

The overall market sentiment has been hit hard by MACRO concerns. The dominating narrative is the Fed and the Debt Ceiling.

Via Talk Markets

Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer

May 12, 2023

From Veracyte, Inc.

Via Business Wire

A New Groundbreaking Tool to Detect Colon Cancer Earlier

May 10, 2023

A novel blood test for detecting colon cancer, the third most lethal type of cancer in the US, has been created. The Colorectal Cancer Screening Blood Test can identify cancer at early stages. This...

Via PressReach

Something Happened In Biotech Last Week ↗

May 08, 2023

Biotech stocks were more constructive last week with some sharp moves up.

Via Talk Markets

Veracyte Announces First Quarter 2023 Financial Results

May 04, 2023

From Veracyte, Inc.

Via Business Wire

New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules

May 04, 2023

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For May 4, 2023 ↗

May 04, 2023

Companies Reporting Before The Bell • Cedar Fair (NYSE:FUN) is estimated to report quarterly loss at $1.83 per share on revenue of $104.21 million.

Via Benzinga

New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients

May 03, 2023

From Veracyte, Inc.

Via Business Wire

New Artificial Intelligence Tool Can Diagnose Colon Cancer

May 03, 2023

A new artificial intelligence (AI) model developed by Harvard Medical School and Taiwan’s National Cheng Kung University could provide much-needed clarity to clinicians presenting prognoses and...

Via PressReach

Topics Artificial Intelligence Death

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.